Senti Biosciences, Inc. (SNTI)
Automate Your Wheel Strategy on SNTI
With Tiblio's Option Bot, you can configure your own wheel strategy including SNTI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SNTI
- Rev/Share 0.5848
- Book/Share 3.781
- PB 0.5633
- Debt/Equity 0.857
- CurrentRatio 4.2153
- ROIC -0.7954
- MktCap 55552743.0
- FreeCF/Share -4.372
- PFCF -1.269
- PE -0.3893
- Debt/Assets 0.392
- DivYield 0
- ROE -1.7725
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SNTI | Laidlaw | -- | Buy | -- | $5 | June 6, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Moderated webcast fireside chat with members of Senti management and Chardan senior research analyst, Geulah Livshits, PhD on Monday, June 9th at 3:00 PM ET Moderated webcast fireside chat with members of Senti management and Chardan senior research analyst, Geulah Livshits, PhD on Monday, June 9th at 3:00 PM ET
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc
Published: May 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Read More
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation Into Senti Biosciences Inc
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ:SNTI). Investors who purchased Senti securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SNTI.
Read More
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Into Senti Biosciences Inc
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Reach Out
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ:SNTI). Investors who purchased Senti securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SNTI.
Read More
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Biosciences Inc
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ:SNTI). Investors who purchased Senti securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SNTI.
Read More
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Investors to Connect
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ:SNTI). Investors who purchased Senti securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SNTI.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Stockholders to Inquire about Securities Investigation
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ:SNTI). Investors who purchased Senti securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SNTI.
Read More
Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
SENTI-202 currently being evaluated in Phase 1 study for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia SENTI-202 currently being evaluated in Phase 1 study for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ:SNTI). Investors who purchased Senti securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SNTI.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Investors to Reach Out
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ:SNTI). Investors who purchased Senti securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SNTI.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ:SNTI). Investors who purchased Senti securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SNTI.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm
Published: May 15, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
Published: May 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Video illustrates SENTI-202's MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuit Video illustrates SENTI-202's MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuit
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc.("Senti" or the "Company") (NASDAQ:SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite Complete Remission (cCR) (3 CR, 1CRh), all 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care; All cCR patients maintaining responses, from 4+ to 8+ months ongoing Ongoing enrollment in Phase 1 SENTI-202 study to confirm the preliminary recommended Phase 2 dose (RP2D) followed by disease specific expansion cohorts Logic-Gated cell therapy approach may have the potential for broad liquid and solid tumor applications, …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. ("Senti" or the "Company") (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI
Published: May 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
About Senti Biosciences, Inc. (SNTI)
- IPO Date 2021-05-26
- Website https://www.sentibio.com
- Industry Biotechnology
- CEO Dr. Timothy K. Lu M.D., Ph.D.
- Employees 34